Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. Neoadjuvant therapy is often used to reduce the size of tumors, especially in locally advanced tumors. The purpose of this therapy is to make part of patients operable and to facilitate breast-conserving surgery. The purpose of this study is to assess the efficacy and safety of the following two proposals: nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin, in order to provide support for rational clinical application. The total number of patients to be included in this study is 520 patients.

NCT Number	NCT04138719
Lead Sponsor	Hebei Medical University Fourth Hospital Collaborators: Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions	Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
Enrollment	520 participants
Start Date	2019-11-20
Primary Completion	2026-10-20 (estimated)
Study Completion	2028-06-20 (estimated)
Updated on ClinicalTrials.gov	2025-09-11